Key takeaways

  • Carvykti (ciltacabtagene autoleucel) is a prescription drug used to treat certain types of multiple myeloma in adults.
  • Carvykti is given as an intravenous (IV) infusion, which is an injection into a vein given over a period of time. It’s typically given as a one-time IV infusion.
  • The dosage you’re prescribed will depend on certain factors such as your body weight.

The active ingredient in Carvykti is ciltacabtagene autoleucel. Carvykti belongs to a group of drugs called chimeric antigen receptor (CAR) T-cell therapy.

This article describes the dosage of Carvykti, including its form and how it’s administered.

Carvykti is available as a liquid solution given as an intravenous (IV) infusion (an injection into a vein over a period of time).

Carvykti is approved to treat certain types of multiple myeloma. You’ll typically receive a one-time dosage of Carvykti. Your doctor will determine your dose based on your body weight in kilograms (kg). For reference, 1 kg is equal to about 2.2 pounds (lb).

Carvykti is administered as an IV infusion by a doctor, nurse, or other healthcare professional. The drug is typically given as a one-time dose, and the infusion lasts about 30 to 60 minutes.

After receiving your Carvykti infusion, you’ll need to remain in the treatment center for at least 7 days. Then, you’ll stay near the treatment center for at least 2 more weeks so that your doctor can monitor you closely for serious side effects.

If you have questions about receiving Carvykti infusions, talk with your doctor.

Disclaimer: Healthline has made every effort to make certain that all information is factually correct, comprehensive, and up to date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or another healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.